Acurx Pharmaceuticals Inc. Common Stock

Acurx Pharmaceuticals Inc. a clinical stage biopharmaceutical company develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C a potential oral and parenteral treatment targeting gram-positive bacteria including methicillin-resistant staphylococcus aureus vancomycin-resistant enterococcus and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island New York.